318,072 Shares in CeriBell (NASDAQ:CBLL) Purchased by Adage Capital Partners GP L.L.C.

Adage Capital Partners GP L.L.C. bought a new position in shares of CeriBell (NASDAQ:CBLL - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 318,072 shares of the company's stock, valued at approximately $8,232,000. Adage Capital Partners GP L.L.C. owned 0.89% of CeriBell as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently bought and sold shares of CBLL. Rhumbline Advisers purchased a new position in shares of CeriBell in the fourth quarter valued at about $320,000. Corebridge Financial Inc. bought a new position in shares of CeriBell during the fourth quarter worth $158,000. PNC Financial Services Group Inc. bought a new stake in CeriBell in the 4th quarter valued at $47,000. Massachusetts Financial Services Co. MA bought a new stake in CeriBell in the fourth quarter worth $10,750,000. Finally, Vanguard Group Inc. purchased a new stake in shares of CeriBell in the fourth quarter worth approximately $18,015,000.

Analyst Ratings Changes

A number of research firms have commented on CBLL. Canaccord Genuity Group reiterated a "buy" rating and issued a $33.00 price target on shares of CeriBell in a research note on Wednesday, February 26th. LADENBURG THALM/SH SH began coverage on shares of CeriBell in a research note on Friday, April 4th. They issued a "buy" rating and a $32.00 price objective on the stock. Seven equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, CeriBell has an average rating of "Buy" and an average target price of $32.50.

CeriBell Stock Performance

Shares of CeriBell stock traded up $0.04 during trading hours on Friday, reaching $16.32. The company's stock had a trading volume of 208,040 shares, compared to its average volume of 270,817. The business's 50 day moving average price is $19.03. CeriBell has a one year low of $10.01 and a one year high of $32.75.

CeriBell (NASDAQ:CBLL - Get Free Report) last released its quarterly earnings data on Tuesday, February 25th. The company reported ($0.40) EPS for the quarter, missing analysts' consensus estimates of ($0.32) by ($0.08). The company had revenue of $18.53 million during the quarter, compared to analysts' expectations of $17.55 million. As a group, sell-side analysts predict that CeriBell will post -2.46 earnings per share for the current year.

Insider Buying and Selling

In other CeriBell news, CEO Xingjuan Chao sold 5,700 shares of the business's stock in a transaction dated Thursday, April 17th. The stock was sold at an average price of $15.02, for a total value of $85,614.00. Following the completion of the transaction, the chief executive officer now directly owns 746,451 shares of the company's stock, valued at approximately $11,211,694.02. The trade was a 0.76 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders have sold a total of 24,700 shares of company stock worth $372,434 in the last 90 days.

CeriBell Company Profile

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.